Horizon Pharma (HZNP) Offers H116 Net Sales, adj.-EBITDA Outlook; Provides Q1 Prescription Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Horizon Pharma (HZNP) Offers H116 Net Sales, adj.-EBITDA Outlook; Provides Q1 Prescription Results
April 14, 2016 9:40 AM EDT
Brean Capital maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $30.00 (from $32.00), after the company provided soft 1Q and 2Q guidance. The company now expects to generate 19-20%/22-23%/57-59% of FY16 sales vs. previous consensus estimates of... More
April 13, 2016 8:20 AM EDT
UBS maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $24.00 (from $39.00), after meeting with management. Horizon is expecting the 1H16 to be slower than 2H16 as it needs to absorb the deductibles that patients cover before drug... More
April 13, 2016 7:55 AM EDT
Piper Jaffray maintained an Overweight rating and $44.00 price target on Horizon Pharma (NASDAQ: HZNP) after the stock loses over a quarter of its value following detail from management regarding the cadence of expected quarterly results. Management cited a higher than expected gross-to-net spreads as one driver associated with lower 1Q16 EPS contribution versus other... More
